Articles tagged with Neoantigens
Researchers are developing neoantigen-based dendritic cell vaccines that aim to train the immune system to recognize tumor-specific mutations and trigger targeted immune responses against cancer cells. Clinical trials have shown promising results, with patient-derived DC vaccines triggering strong, durable immune responses, delaying tu...
The review highlights how T cells specifically recognize and eliminate malignant cells through antigen recognition mechanisms. It also explores how tumors evade immune surveillance through various mechanisms and discusses potential therapeutic strategies, including combination therapies to improve response rates for cancer patients.
Researchers at La Jolla Institute for Immunology discovered that ALS is likely caused by an autoimmune reaction triggered by inflammatory CD4+ T cells targeting specific proteins in the nervous system. Anti-inflammatory CD4+ T cells may slow disease progression and prolong survival times.
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.
Cancer vaccines hold transformative potential, leveraging neoantigens to activate the immune system against tumors. UK researchers are positioning themselves for a strategic shift in cancer vaccine trials, recognizing opportunities for improvement.
Researchers at Tokyo University of Science found that kaempferol increases RALDH2 levels in dendritic cells, promoting regulatory T-cell development and reducing inflammation. The study suggests that flavonoids like kaempferol may serve as natural remedies to alleviate allergic symptoms.
A Phase 1 study evaluates an individualized neoantigen therapy, showing it is well-tolerated and boosts immune activity against cancer-causing cells. The therapy induces multiple forms of T cell proliferation and sustained responses in patients with melanoma and lung cancer.
A new clinical trial demonstrates a novel, personalized neoantigen vaccine therapy showed promising anti-tumor efficacy in patients with liver cancer who failed their original front-line treatment. The therapy induced potent induction of T cell immunity and regressed tumors in preclinical model studies.
A personalized vaccine, TG4050, has been shown to induce tumor-specific immune responses and delay disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine uses a nonpathogenic form of poxvirus to deliver unique neoantigens that activate and expand antitumor T cells.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
A new computational tool, SNAF, has been developed to identify shared splicing neoantigens that can help a patient's immune system fight cancer. The tool has already uncovered promising targets for melanoma and other cancers.
A new machine-learning method, BigMHC, can accurately predict cancer-related protein fragments that may trigger an immune system response. By leveraging massive data through transfer learning, BigMHC enables scientists to develop personalized immunotherapies and vaccines by identifying the most likely to provoke an immune response.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.
Researchers at German Cancer Research Center successfully tested a protective vaccination against hereditary colorectal cancer in mice, achieving a significant delay in tumor development. Combining the vaccine with an anti-inflammatory drug further increased its effectiveness, showing promise for future clinical applications.
A study characterized genomic and neoantigen evolution between primary and first recurrence tumors in 23 HNSCC patients, identifying shared genes with predicted neoantigens. Patients with these shared neoantigens tend to have increased duration of survival with disease.
The Tumor Neoantigen Selection Alliance (TESLA) has discovered five characteristics that strongly indicated which cancer markers were most likely to generate an immune response. The data model accurately predicted 75% of effective neoantigen targets and filtered out 98% of ineffective ones.
A preclinical study has shown that a cancer preventive vaccine may be effective in preventing cancers associated with Lynch syndrome. The vaccine was found to reduce intestinal tumor burden and improve survival in mice with the genetic mutation, suggesting potential as a treatment option.
This study developed a personalized approach to inducing immunity against unique combinations of tumor neoantigens, resulting in higher CD8+ T-cell immunity and delayed tumor growth. The vaccine platform successfully killed tumor cells, slowed tumor progression, and prolonged survival in preclinical models.
Researchers have developed techniques to personalize anticancer vaccines based on individual patient genomic information, targeting unique tumor mutations. Early results show promise in inducing potent immune responses.
A new treatment aims to direct an immune response against a misshapen protein found exclusively on cancer cells, offering hope for children with deadly diffuse intrinsic pontine glioma. The protein target is a neoantigen that can be used to develop more selective and potent immunotherapies.
A personal neoantigen vaccine has been shown to stimulate a potent, safe, and highly specific immune response in melanoma patients. The vaccine targets distinctive 'neoantigens' on tumor cells, inducing a focused T cell response against several tumor neoantigens.
Researchers developed personalized melanoma vaccines that target unique mutations in each patient's tumor, increasing the number and diversity of cancer-fighting T cells. The vaccines were shown to be safe and effective in a first-in-people clinical trial, setting the stage for potential use in preventing recurrence.